TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36928238
Drug: Progressive muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive muscle relaxation (PMR) plus treatment as usual (TAU)
Study: 33524060
Drug: aboBoNT‐A (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: aboBoNT‐A (500 U in a 2‐mL injection volume)
Study: 32186940
Drug: IVC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVC injection 3 to 5 days before surgery (Group 1)
Study: 32186940
Drug: IVC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVC injection at the end of surgery (Group 2)
Study: 32186940
Drug: IVC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVC injection 3 to 5 days before and at the end of operation (Group 3)
Study: 35964868
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure for Primary Care (PE-PC) treatment
Study: 33982219
Drug: TFES +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFES + biofeedback therapy
Study: 36508996
Drug: Xanthohumol (Xn)
Normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthohumol (Xn) at a daily dose of 4.5 mg/kg body weight for 7 days
Study: 35939810
Drug: Ensovibep (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensovibep (600 mg intravenous)
Study: 32569258
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for PID (current national treatment guidelines)
Study: 33507248
Drug: Mifepristone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (50 mg every 6 h for 9 days)
Study: 34955488
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy without endovascular therapy
Study: 35942813
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 mcg OD)
Study: 36076231
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy Skills Intervention (CBTSI)
Study: 35270556
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of caffeine (CAF-3)
Study: 35270556
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg of caffeine (CAF-6)
Study: 32299437
Drug: Projected daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Projected daily capacity for screening
Study: 34392411
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU of daily vitamin D3
Study: 34392411
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU of daily vitamin D3
Study: 32718193
Drug: Budesonide/formoterol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol as maintenance and reliever therapy
Study: 32953229
Drug: C1INH (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1INH (SC) 40 or 60 IU/kg twice weekly for 52-140 weeks
Study: 33792003
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered heparin
Study: 33792003
Drug: Control ointment
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control ointment (dexpanthenol)
Study: 35108780
Drug: Low-flow anesthesia
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow anesthesia (1 L/min)
Study: 35108780
Drug: High-flow anesthesia
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow anesthesia (2 L/min)
Study: 33788459
Drug: Long-snake moxibustion
Normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-snake moxibustion combined with western medication (loperamide hydrochloride and bacillus licheniformis)
Study: 33788459
Drug: Simple medication
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple medication (loperamide hydrochloride and bacillus licheniformis)
Study: 32757577
Drug: Integrated Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Intervention for Dual Problems and Early Action (IIDEA), a 10-session manualized intervention that includes cognitive therapy and mindfulness practice.
Study: 32757577
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (usual treatment plus scheduled assessments)
Study: 33591618
Drug: semaglutide 0.25
Normalized name: SEMAGLUTIDE 0.25MG/0.375ML INJ PEN 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 0.25 mg
Study: 36184780
Drug: dulaglutide 0.75
Normalized name: DULAGLUTIDE 0.75MG/0.5ML INJ PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: dulaglutide 0.75 mg
Study: 36153634
Drug: Online Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Cognitive Behavioral Therapy for Insomnia (OCBT-I) + Positive Airway Pressure (PAP) therapy
Study: 36153634
Drug: Therapist-delivered Cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-delivered Cognitive Behavioral Therapy for Insomnia (TCBT-I)
Study: 33742252
Drug: Carboxy therapy
Normalized name: α-carboxy-3-thienylmethylpenicillin
DrugBank: Ticarcillin (DB01607)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carboxy therapy
Study: 34063068
Drug: NATUREN G®
Approvals — FDA: no, EMA: no, PMDA: no
Description: NATUREN G® (synbiotic formulation)
Study: 32639946
Drug: Survival nomogram
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survival nomogram based on five clinicopathological features (race, AJCC stage, surgery for primary site, chemotherapy, tumor size)
Study: 36351326
Drug: Early time-restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early time-restricted eating (eTRE) with a daily 6-hour eating window
Study: 36351326
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CON) with a daily 16-hour eating window
Study: 33516458
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy (n = 36)
Study: 33516458
Drug: Treatment waiting
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment waiting list (n = 30)
Study: 33038066
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium meal (HSM; 1,495 mg Na+)
Study: 33038066
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium meal (LSM; 138 mg Na+)
Study: 36367444
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of habitat manipulation and permanent change (habitat modification)
Study: 36367444
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of manipulation and modification with larviciding
Study: 33839747
Drug: Pretransplant bridging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretransplant bridging therapy
Study: 33839747
Drug: Controlled disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled disease (under bridging therapy)
Study: 32317673
Drug: Cadmium concentration
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadmium concentration in plants (0, 10, and 100 mg kg‐1 soil)
Study: 32317673
Drug: Mercury concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mercury concentration in plants (0, 2, and 20 mg kg‐1 soil)
Study: 35840747
Drug: Low-dose PTCy-ATG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PTCy-ATG (20 mg/kg on day +3 and +4, 6 mg/kg ATG)
Study: 34530679
Drug: Developmentally adapted
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmentally adapted cognitive processing therapy (D‐CPT)
Study: 32918100
Drug: Wait-list with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list with treatment advice (WL/TA)
Study: 33155236
Drug: Individualized antiplatelet
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized antiplatelet therapy based on CYP2C19 genotype and platelet function (IA group)
Study: 36060969
Drug: MET plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET plus LIRA therapy
Study: 36060969
Drug: MET monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET monotherapy
Study: 33269975
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate (NOMAc) 10 mg/day and transdermal 17-beta-estradiol (E2) 75 µg/week
Study: 35109837
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of tranexamic acid (TXA)
Study: 39661358
Drug: Guselkumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab treatment
Study: 32072618
Drug: No information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: No information on medication's efficacy or safety profile
Study: 35101419
Drug: Low-dose warfarin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose warfarin (target INR 2.0 to 2.5)
Study: 35101419
Drug: Standard-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose warfarin (target INR 2.5 to 3.5)
Study: 32919056
Drug: High-intensity interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity interval training (5-6 times weekly for 60 days)
Study: 33397457
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus 1000 mg of nitazoxanide twice daily and 300/100 mg of atazanavir/ritonavir once daily orally
Study: 33654379
Drug: Combination analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination analgesia (oral celebrex, pregabalin, and subcutaneous infiltration of ropivacaine)
Study: 33654379
Drug: Ropivacaine (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (only subcutaneous infiltration of ropivacaine)
Study: 36288594
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of dexamethasone
Study: 32533792
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and etodolac (COX2-inhibitor) administered for 20 perioperative days, starting 5 days before surgery.
Study: 32533792
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and etodolac (treatment group).
Study: 32533792
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and etodolac (treatment group, protocol-compliant patients).
Study: 33543655
Drug: Melatonin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (18 mg/day) from 1 week before until 1 month after adjuvant radiotherapy
Study: 34491543
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite infusion for 1 hour
Study: 34491543
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion for 1 hour
Study: 35010998
Drug: Dihydroberberine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroberberine 100 mg (D100)
Study: 35010998
Drug: Dihydroberberine 200
Normalized name: Dihydroberberine 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroberberine 200 mg (D200)
Study: 35010998
Drug: Berberine 500
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine 500 mg (B500)
Study: 36379612
Drug: Two-stage regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-stage regional citrate anticoagulation (RCA) with 0.04 g/mL sodium citrate infusion for 3 hours during dialysis
Study: 33413942
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (CaCl2) injection (2 ml of 5%) into the major atrial ganglionated plexi during CABG
Study: 33413942
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (0.9%) injection (sham control) into the major atrial ganglionated plexi during CABG
Study: 33413942
Drug: Calcium chloride
Normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium chloride (CaCl2) injection
Study: 34545949
Drug: Luseogliflozin (SGLT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin (SGLT2 inhibitor)
Study: 32483061
Drug: Eccentric training
Normalized name: SYRINGE 60ML ECCENTRIC TIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eccentric training (twice-weekly for 6 weeks)
Study: 32460786
Drug: ARCHES intervention
Normalized name: arched swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCHES intervention (treatment condition)
Study: 32384205
Drug: 577-nm high-power
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 577-nm high-power optically pumped semiconductor laser (HOPSL) treatment
Study: 34032204
Drug: Daclatasvir hydrochloride
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir hydrochloride tablets (60 mg) under fasting conditions
Study: 34032204
Drug: Daclatasvir hydrochloride
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir hydrochloride tablets (60 mg) under postprandial conditions
Study: 33536253
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin only (Control)
Study: 35690997
Drug: AH8 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH8 10% lotion formulated in Cetaphil Moisturizing Facial Lotion
Study: 35643956
Drug: ORAL Surveillance
Normalized name: LANCET,SURGILANCE SAFETY
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL Surveillance trial
Study: 32665999
Drug: Alpha-adrenoreceptor blocker
Normalized name: Alpha-adrenoreceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenoreceptor blocker only (Control)
Study: 35366393
Drug: Combined social
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined social communication therapy at home and in education
Study: 32508977
Drug: Disposable infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disposable infusion needles with a separation‐free safety tube
Study: 32508977
Drug: Conventional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional infusion needles
Study: 32197911
Drug: Tian‐Tian 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tian‐Tian 120 outdoor program (120 minutes outdoors daily)
Study: 33720069
Drug: Nivolumab added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab added to first-line chemotherapy
Study: 33720069
Drug: Pembrolizumab added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab added to first-line chemotherapy
Study: 35149701
Drug: Gabapentin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (300 mg oral) and Methylprednisolone (125 mg IV)
Study: 34935050
Drug: Self-administered electrotherapy
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered electrotherapy treatment using the Exopulse Mollii Suit®
Study: 36327101
Drug: Netarsudil twice
Normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Netarsudil twice a day (BID)
Study: 32595142
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL 0.25% ropivacaine divided into four injections (two for TAP and two for RS block)
Study: 32577745
Drug: Placebo (mock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (mock titration)
Study: 36286602
Drug: Zolmitriptan nasal
Normalized name: Zolmitriptan Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan nasal spray (ZNS) high dose
Study: 34986394
Drug: Heparin (control)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin (control)
Study: 35306189
Drug: Educational photo
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational photo book about intravenous placement
Study: 36397219
Drug: Low-dose acupuncture
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acupuncture (3 times each chemotherapy cycle for a total of 9 times)
Study: 36397219
Drug: High-dose acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acupuncture (7 times each chemotherapy cycle for a total of 21 times)
Study: 36397219
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional chemotherapy and antiemetic treatment)
Study: 35732399
Drug: Intraperitoneal paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraperitoneal paclitaxel monotherapy, administered through a peritoneal port-a-cath (PAC) system, with 8-16 weekly cycles.
Study: 34302324
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg orally once daily for 14 days every 3 weeks)
Study: 34302324
Drug: Placebo (analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (analogue capsule orally once daily for 14 days every 3 weeks)
Study: 36306479
Drug: Chemotherapy (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (carboplatin + paclitaxel or pemetrexed) for 4-6 cycles with optional maintenance pemetrexed
Study: 34990498
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 15 mg/kg before treatment (preemptive group, n = 35)
Study: 34990498
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received intravenous paracetamol 15 mg/kg at the end of treatment (control group, n = 35)
Study: 33507592
Drug: 750 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/kg/d of standardized extract of Nasturtium officinale (SENO)
Study: 33507592
Drug: 750 mg/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/kg/d of placebo
Study: 32159257
Drug: Garlic supplement
Normalized name: Garlic 300 MG Oral Capsule [GARLIC SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplement (500 mg, 2 tablets daily for 8 weeks)
Study: 32159257
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets daily for 8 weeks)
Study: 34582088
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy using non-ablative fractional laser and intralesional triamcinolone injection
Study: 33704569
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser therapy (n = 19)
Study: 33704569
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser therapy (n = 15)
Study: 33704569
Drug: Er:YAG +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG + Nd:YAG combination therapy (n = 20)
Study: 32335288
Drug: Take a
Normalized name: Take Action
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Take a Break intervention including Motivational Messages, text message Challenge Quizzes, Goal-setting with tobacco treatment specialist, Coping Mini-Games apps, Recognition and Rewards for participation during a 3-week challenge.
Study: 32335288
Drug: Brief Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Nicotine Replacement Therapy (NRT) sampling and daily smoking assessment text messages for three weeks.
Study: 32435906
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBM)
Study: 34537184
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral anticoagulants (NOACs)
Study: 34676440
Drug: Methylphenidate (20
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20 mg, oral)
Study: 33216002
Drug: Telephone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive behavioral therapy (TCBT); n=17 at 3 months and n=13 at 12 months
Study: 33216002
Drug: Web-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive behavioral therapy (WCBT); n=17 at 3 months and n=12 at 12 months
Study: 34000119
Drug: Complicated Grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated Grief Treatment (CGT) with placebo
Study: 33248586
Drug: Feed formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feed formulation with 60% CP soybean meal (SBM)
Study: 33256621
Drug: Rituximab and
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab and maintenance Mycophenolate mofetil (1200 mg/m2 per day starting 3 months after Rituximab)
Study: 33256621
Drug: Repeated courses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated courses of prophylactic Rituximab (administered at 0, 8 and 16 months if B cell count normalizes)
Study: 36325128
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pistachios (3.0 oz/d; PH)
Study: 36325128
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pistachios (1.5 oz/d; PL)
Study: 36325128
Drug: Pistachios (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachios (both doses)